EMA Application withdrawn: Sitoiganap (allogeneic glioma tumor cell lysates (inactivated);allogeneic glioma tumor cells (inactivated);autologous glioma tumor cell lysates (inactivated);autologous glioma tumor cells (inactivated)) — Epitopoietic Research Corporation-Belgium (E.R.C.)

View source ↗

Summary

The EMA has withdrawn the application for Sitoiganap, an immunotherapy consisting of inactivated allogeneic/autologous glioma tumor cell lysates and/or cells fo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioma
• Gliosarcoma

Drugs mentioned

• Sitoiganap

Snippet

Status: Application withdrawn. Therapeutic area: Glioma;Gliosarcoma. MAH: Epitopoietic Research Corporation-Belgium (E.R.C.)